Mazdutide Peptide Profile
Mazdutide (also known as IBI362 or LY3305677) is a synthetic dual agonist peptide analogue that targets both the glucagon‑like peptide‑1 receptor (GLP‑1R) and the glucagon receptor (GCGR), combining the metabolic benefits of incretin signaling with enhanced energy expenditure. It is engineered based on the endogenous hormone oxyntomodulin, incorporating a fatty‑acid side chain to prolong its half‑life for once‑weekly subcutaneous administration. Mazdutide’s dual receptor activity simultaneously enhances glucose‑dependent insulin secretion, suppresses appetite and increases energy expenditure, which supports weight reduction, improved glycemic control, and cardiometabolic benefits such as lowered waist circumference, blood pressure, liver fat content, and lipid parameters in clinical studies. It is under development for the treatment of obesity and type 2 diabetes (T2D) and has received marketing approval in China for chronic weight management — the first dual GLP‑1/GCGR agonist approved globally. Clinical phase III data demonstrate robust weight loss and significant improvements in glycemic outcomes compared with dulaglutide and semaglutide‑type comparators. Mazdutide’s safety profile aligns with that of other incretin‑based therapies, with common adverse effects including gastrointestinal symptoms. (Wikipedia)
Mazdutide Dosing Chart (Investigational / Approved in China)
| Form | Dose | Frequency | Primary Use | Notes |
| Subcutaneous injection | 4 mg | Once weekly | T2D / weight management | Phase III regimen showing efficacy (Nature)
| Subcutaneous injection | 6 mg | Once weekly | T2D / weight management | Demonstrated greater weight loss & glycemic control (Nature)
| Subcutaneous injection | 9–10 mg | Once weekly | Obesity (clinical studies) | Higher doses tested in Phase II/III trials (ScienceDirect)
References (APA):
Mazdutide. (2025). Wikipedia. https://en.wikipedia.org/wiki/Mazdutide (Wikipedia)
Zhang, B., et al. (2024). Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes. Diabetes Care. (Diabetes Journals)
Mazdutide: Phase III results. (2025). Nature / Clinical Trials. (PR Newswire)
